The level of TNF soluble receptor type 1 in patients with systemic sclerosis
- Authors: Alekperov RТ1, Timchenko AV1, Samsonov MY.1, Guseva NG1, Nasonov EL1
-
Affiliations:
- ГУ Институт ревматологии РАМН
- Issue: Vol 79, No 5 (2004)
- Pages: 11-15
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/29786
- ID: 29786
Cite item
Full Text
Abstract
Keywords
About the authors
R Т Alekperov
ГУ Институт ревматологии РАМНМосква; ГУ Институт ревматологии РАМН
A V Timchenko
ГУ Институт ревматологии РАМНМосква; ГУ Институт ревматологии РАМН
M Yu Samsonov
ГУ Институт ревматологии РАМНМосква; ГУ Институт ревматологии РАМН
N G Guseva
ГУ Институт ревматологии РАМНМосква; ГУ Институт ревматологии РАМН
E L Nasonov
ГУ Институт ревматологии РАМНМосква; ГУ Институт ревматологии РАМН
References
- LeRoy E. С., Smith E. A., Kahaleh М. В. et al. A strategy for determining the pathogenesis of systemic sclerosis. Arthr. and Rheum. 1989; 32: 817-825.
- Black С. М. The aetiopathogenesis of systemic sclerosis. J. Roy. Coll. Physic. Lond. 1995; 29: 119-130.
- Pober J. S. Endothelial activation: intracellular signalling pathways. Arthr. Res. 2002; 4 (suppl. 3): S109-S116.
- Cope A. P. Studies of T-cell activation in chronic inflammation. Arthr. Res. 2002; 4 (suppl. 3): S197-S211.
- Zhang M., Tracey K. J. Tumor necrosis factor. In: Thopson A., ed. The cytokine handbook. 3-rd ed. San Diego, Calif.: Academic Press; 1998. 517-548.
- Umehara H., Kumagai S., Murakami M. et al. Enhanced production of interleukin-l and tumor necrosis factor alpha by cultured peripheral blood monocytes from patients with scleroderma. Arthr. and Rheum. 1990; 33 (6): 893-897.
- Kantor Т. V., Friberg D., Medsger Т. A. Jr. et al. Cytokine production and serum levels in systemic sclerosis. Clin. Immunol. Immunopathol. 1992; 65 (3): 278-285.
- Kadono Т., Kikuchi K., Ihn H. et al. Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts. J. Rheumatol. 1998; 25 (2): 296-301.
- Gruschwitz M. S., Vieth G. Up-regulation of class II major histocompatibility complex and intercellular adhesion molecule 1 expression on scleroderma fibroblasts and endothelial cells by interferon-gamma and tumor necrosis factor alpha in the early disease stage. Arthr. and Rheum. 1997; 40 (3): 540-550.
- Cho M. M., Jimenez S. A., Johnson B. A. et al. In vitro cytokine modulation of intercellular adhesion molecule-1 expression on systemic sclerosis dermal fibroblasts. Pathobiology 1994; 62 (2): 73-81.
- Hasegawa M., Fujimoto M., Kikuchi K., Takehara K. Elevated serum tumor necrosis factor-alpha levels in patients with systemic sclerosis: association with pulmonary fibrosis. J. Rheumatol. 1997; 24 (4): 663-665.
- Van Zee K. J., Kohno Т., Fisher E. et al. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc. Natl. Acad. Sci. USA 1992; 89: 4845-4849.
- Van Zee K. J., Stackpole S. A., Montegur W. J. et al. A human tumor necrosis factor (TNF) mutant that binds exclusively to the p55 TNF receptor produces toxicity in the baboon. J. Exp. Med. 1994; 179: 1185-1191.
- Sheehan K. C., Pinckard J. K., Arthur С. D. et al. Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: identification of a novel in vivo role for p75. J. Exp. Med. 1995; 181:607-617.
- Heilig В., Fiehn C., Brockhaus M. et al. Evaluation of soluble tumor necrosis factor (TNF) receptors and TNF receptor antibodies in patients with systemic lupus erythematodes, progressive systemic sclerosis, and mixed connective tissue disease. J. Clin. Immunol. 1993; 13 (5): 321-328.
- Majewski S., Wojas-Pelc A., Malejczyk M. et al. Serum levels of soluble TNF alpha receptor type I and the severity of systemic sclerosis. Acta Dermato-Venereol. 1999; 79 (3): 207-210.
- D'Elios M. M., Romagnani P., Scaletti С. et al. In vivo CD30 expression in human diseases with predominant activation of Th2-like T cells. J. Leukoc. Biol. 1997; 61 (5): 539-544.
- Gruschwitz M. S., Albrecht M., Vieth G., Haustein U. F. In situ expression and serum levels of tumor necrosis factor-alpha receptors in patients with early stages of systemic sclerosis. J. Rheumatol. 1997; 24 (10): 1936-1943.
- MasiA. Т., Rodnan G. P., Medsger T. A. et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthr. and Rheum. 1980; 23: 581-590.
- LeRoy E. C., Black С. М., Fleischmajer R. et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J. Rheumatol. 1988; 15: 202-205.
- Valentini G., Delia Rossa A., Bombardieri S. et al. European multicenter study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann. Rheum. Dis. 2001; 60: 592-598.
- Kahaleh M. В., Sultany G. L., Smith E. A. et al. A modified scledroderma skin scoring method. Clin. Exp. Rheumatol. 1986; 4: 367-369.
- Bevilacqua M. P., Pober J. S., Wheeler M. E. et al. Interleukin1 acts on cultured human vascular endothelial cells to increase the adhesion of polymorphonuclear leukocytes, monocytes and related leukocyte cell lines. J. Clin. Invest. 1985; 76: 2003- 2011.
- Pober J. S., Cotran R. S. Cytokines and endothelial cell biology. Physiol. Rev. 1990; 70: 427-451.
- Denton С. P., Bickerstaff M. С. М., Shiwen X. et al. Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. Br. J. Rheumatol. 1995; 34 (11): 1048-1054.
- Bolster M. В., Ludwicka A., Sutherland S. E. et al. Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthr. and Rheum. 1997; 40 (4): 743-751.
- Pantelidis P., McGrath D. S., Southcott A. M. et al. Tumour necrosis factor-alpha production in fibrosing alveolitis is macrophage subset specific. Respir. Res. 2001; 2 (6): 365-372.